Data Bytes: Phase I TIGIT data emphasize importance of patient selection

Phase I data from Genentech’s high-profile anti-TIGIT mAb tiragolumab suggest choosing the right indications and patient subsets will be key to success for next-generation checkpoint inhibitors.

The data, presented at the American Association for Cancer Research Virtual Meeting II, showed signals in non-small cell lung cancer (NSCLC) and head and neck cancer in a small number of patients treated with tiragolumab plus PD-L1 inhibitor Tecentriq atezolizumab, but no responses in patients treated with tiragolumab monotherapy or in other types of solid tumors. ...